BORTEZOMIB PLUS MELPHALAN AND PREDNISONE IN UNTREATED PATIENS WITH MULTIPLE MYELOMA INELIGIBLE FOR STEM CELL TRASPLANTATION

被引：0

作者：

Sanchez, R. Garcia ^{[1
]}

Entrena, L. ^{[1
]}

Hernandez, A. ^{[2
]}

Gonzalez, P. ^{[3
]}

Puerta, J. M. ^{[2
]}

Pascual, A. ^{[4
]}

Castellanos, M. ^{[5
]}

Morales, E. ^{[5
]}

Casanova, M. ^{[6
]}

Bailen, A. ^{[7
]}

Duran, S. ^{[3
]}

Almagro, M. ^{[2
]}

Ramirez, G. ^{[1
]}

Del Castillo, S. ^{[1
]}

机构：

[1] Hosp Virgen Victoria, Malaga, Spain

[2] Hosp Virgen Nieves, Jaen, Spain

[3] Hosp Jaen, Jaen, Spain

[4] Hosp Ubeda, Jaen, Spain

[5] Hosp Torrecardenas, Almeria, Spain

[6] Hosp Costa Sol, Marbella, Spain

[7] Hosp Carlos Haya, Malaga, Spain

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1487

引用

页码：592 / 592

页数：1

共 50 条

[1] Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M. -V.
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pour, L.
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. -S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (06): : 518 - 528
[2] Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
Xie, Dan
Zhang, Peng-Fei
BMJ OPEN, 2025, 15 (02):
[3] Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
Avvisati, Giuseppe
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2613 - 2613
[4] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Kobos, Rachel
San-Miguel, Jesus
BLOOD, 2019, 134
[5] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Grosicki, Sebastian
Crepaldi, Andre
Liberati, Anna Marina
Campbell, Philip
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Iida, Shinsuke
Blade, Joan
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Kudva, Anupa
Qi, Ming
San-Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
[6] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
San Miguel, Jesus F.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie L.
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul G.
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09): : 906 - 917
[7] Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
Zweegman, Sonja
van der Holt, Bronno
Mellqvist, Ulf-Henrik
Salomo, Morten
Bos, Gerard M. J.
Levin, Mark-David
Visser-Wisselaar, Heleen
Hansson, Markus
van der Velden, Annette W. G.
Deenik, Wendy
Gruber, Astrid
Coenen, Juleon L. L. M.
Plesner, Torben
Klein, Saskia K.
Tanis, Bea C.
Szatkowski, Damian L.
Brouwer, Rolf E.
Westerman, Matthijs
Leys, M. B. L.
Sinnige, Harm A. M.
Haukas, Einar
van der Hem, Klaas G.
Durian, Marc F.
Mattijssen, E. J. M.
van de Donk, Niels W. C. J.
Stevens-Kroef, Marian J. P. L.
Sonneveld, Pieter
Waage, Anders
BLOOD, 2016, 127 (09) : 1109 - 1116
[8] Bortezomib plus melphalan and prednisone (VMP) in elderly untreated patients with multiple myeloma:: Prognostic factors influencing time to progression
Mateos, M.-V. M.
Hernandez, J.-M.
Hemandez, M.-T.
Gutierrez, N.-C.
Palomera, L.
Fuertes, M.
Garcia, P.
Lahuerta, J. J.
De la Rubia, J.
Terol, M. J.
Sureda, A.
Bargay, J.
Ribas, P.
De Arriba, E.
Alegre, A.
Oriol, A.
Carrera, D.
Garcia-Larana, J.
Garcia-Sanz, R.
Bladé, J.
Prosper, F.
Esseltine, D.-L.
Van de Velde, H.
San-Miguel, J.-F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 148 - 149
[9] Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
Mateos, Maria-Victoria
Hernandez, Jose-M.
Hernandez, Miguel-T
Gutierrez, Norma-C.
Palomera, Luis
Fuertes, Marta
Diaz-Mediavilla, Joaquin
Lahuerta, Juan-J.
de la Rubia, Javier
Terol, Maria-Jose
Sureda, Ana
Bargay, Joan
Ribas, Paz
de Arriba, Felipe
Alegre, Adrian
Oriol, Albert
Carrera, Dolores
Garcia-Larana, Jos
Garcia-Sanz, Ramon
Blade, Joan
Prosper, Felipe
Mateo, Gemma
Esseltine, Dixie-Lee
de Velde, Helgi van
San Miguel, Jesus-F.
BLOOD, 2006, 108 (07) : 2165 - 2172
[10] Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Lee, Se Ryeon
Choi, Hojoon
Lee, Byung Hyun
Kang, Ka-Won
Yu, Eun Sang
Kim, Dae Sik
Park, Yong
Choi, Chul Won
Kim, Byung Soo
Sung, Hwa Jung
KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06): : 1333 - 1346

← 1 2 3 4 5 →